Constitutive activation of the NF-κB pathway through genetic aberrations and signals from the tumour microenvironment plays a major oncogenic role in GC-derived lymphomas, identifying inhibition of NF-κB signaling as a conceivable strategy for lymphoma treatment. The gene discussed is NFKB1; the disease is lymphoma.